Historical perspectives pertaining to the NIH recombinant DNA advisory committee

Human Gene Therapy

Volumn 25, Issue 1, 2014, Pages 19-24

  Wivel, Nelson A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN BETA CHAIN; INTERLEUKIN 2; RECOMBINANT DNA; RETROVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOSINE DEAMINASE DEFICIENCY; ADVISORY COMMITTEE; ANTIGEN RECOGNITION; BONE MARROW CELL; CHRONOLOGY; CYTOTOXIC T LYMPHOCYTE; DEVELOPMENTAL STAGE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GLIOBLASTOMA; GOVERNMENT REGULATION; HEAD AND NECK CANCER; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE RESPONSE; LAW; MELANOMA CELL; MOLECULAR GENETICS; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL TRANSPLANTATION; THALASSEMIA; TUMOR ASSOCIATED LEUKOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADVISORY COMMITTEES; DNA, RECOMBINANT; GENETIC THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 84892865059     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.2524     Document Type: Review

References (16)

1. Berg, P., Baltimore, D., Boyer, H. W., et al. (1974). Letter: Potential hazards of recombinant DNA molecules. Science 185, 303.
2. National Institutes of Health (1989a). Minutes of the Recombinant DNA Advisory Committee. January 30, 6-14.
3. National Institutes of Health (1989b). Minutes of the Recombinant DNA Advisory Committee. October 6, 25-27.
4. National Institutes of Health (1990a). Minutes of the Recombinant DNA Advisory Committee. February 5, 25-27.
5. National Institutes of Health (1990b). Minutes of the Recombinant DNA Advisory Committee. March 30, 4-7.
6. National Institutes of Health (1990c). Minutes of the Recombinant DNA Advisory Committee. July 31, 3-17.
7. National Institutes of Health (1991). Minutes of the Recombinant DNA Advisory Committee. October 7, 25-29.
8. National Institutes of Health (1992). Minutes of the Recombinant DNA Advisory Committee. February 10, 37-41.
9. National Institutes of Health (1994). Minutes of the Recombinant DNA Advisory Committee. September 12, 43-48.
10. National Institutes of Health (1995). Ad hoc Review Committee of the Recombinant DNA Advisory Committee. Executive Summary of Findings and Recommendations, September 8.
11. National Institutes of Health (1997). Minutes of the Recombinant DNA Advisory Committee. March 6, 4-17.
12. Notice of Intent to propose amendments to the NIH Guidelines for Research Involving Recombinant DNA Molecules regarding enhanced mechanisms for NIH oversight of recombinant DNA activities (1996). Federal Register (96FR35744), July 8, 35744-35777.
13. Office of Technology Assessment (1987). New Developments in Biotechnology-Background Paper: Public Perceptions of Biotechnology. U. S. Government Printing Office. Washington, D. C. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research (1982).
14. Splicing Life: The Social and Ethical Issues of Genetic Engineering with Human Beings. U. S. Government Printing Office. Washington, D. C. Protection of Human Subjects (45CFR46) (1983). Federal Register (48FR9269), March 4.
15. Walters, L. (1991). Human gene therapy: ethics and public policy. Hum. Gene Ther. 2, 115-122.
16. Wivel, N. A., and Anderson, W. F. (1998). Human gene therapy: public policy and regulatory issues. In The Development of Human Gene Therapy. T. Friedmann, ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 671-689.